Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Gastroenterology
Erschienen in: Current Treatment Options in Gastroenterology 4/2016

08.10.2016 | Stomach (K Koch, Section Editor)

Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis

verfasst von: Kimberly N. Harer, MD, Pankaj J. Pasricha, MD

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Opinion statement

Chronic unexplained nausea and vomiting is a debilitating condition that dramatically decreases patient quality of life and creates diagnostic and treatment challenges for healthcare providers. Additionally, the significant overlap in symptoms between disorders such as chronic unexplained nausea and vomiting, gastroparesis, and functional dyspepsia has resulted in a blurring of diagnostic lines and added confusion to the therapeutic approach. The identified overlap in clinical symptoms also suggests a common underlying pathophysiological mechanism may drive these conditions, indicating they could possibly be part of a spectrum of gastric neuromuscular disorders instead of discrete processes. This article will discuss the classification, updates in pathophysiology and therapeutic research, and future directions of research in the treatment of chronic unexplained nausea and vomiting.
Literatur
1.••
Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 150:1380–92. This article outlines the Rome IV criteria for Functional Gastrointestinal Disorders, focusing on gastroduodenal disorders such as functional dyspepsia and Chronic Nausea and Vomiting Syndrome.
2.••
Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:567–76. Multi-center study published by the Gastroparesis Consortium that compared patients with gastroparesis symptoms and either delayed emptying (gastroparesis) or normal gastric emptying (CUNV). Investigators found the two groups to be clinically indistinguishable.CrossRefPubMedPubMedCentral
3.
Anaparthy R, Pehlivanov N, Grady J, et al. Gastroparesis and gastroparesis-like syndrome: response to therapy and its predictors. Dig Dis Sci. 2009;54:1003–10.CrossRefPubMedPubMedCentral
4.
Olden KW, Crowell MD. Chronic nausea and vomiting: new insights and approach to treatment. Curr Treat Options Gastroenterol. 2005;8:305–10.CrossRefPubMed
5.
Drossman DA, Corazziari E, Delvaux M, et al. Rome III: the functional gastrointestinal disorders. 130 ed; 2006. p. 1377–556.
6.
Dibaise JK, Islam RS, Dueck AC, et al. Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying. Neuroenterol Motil. 2016;28:196–205.CrossRef
7.
Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol. 2001;96:1422–8.CrossRefPubMed
8.
Karamanolis G, Caenepeel P, Arts J, et al. Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut. 2007;56:29–36.CrossRefPubMed
9.
Samsom M, Vermeijden JR, Smout AJ, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care. 2003;26:3116–22.CrossRefPubMed
10.
Janssen P, Van Oudenhove L, Bisschops R, Tack J. Idiopathic gastroparesis or functional dyspepsia with delayed gastric emptying: where is the difference? Gastroenterology. 2011;140(7):2145–6.CrossRefPubMed
11.•
Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut. 2014;63(12):1972–8. This article discusses the clinical overlap between gastroparesis and dyspepsia and discusses how the two disorders may be part of a disease spectrum.CrossRefPubMed
12.••
Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. 2011;140(5):1575–85. Prospective case-control trial with full-thickness gastric biopsy specimens demonstrating cellular abnormalities in gastroparesis patients, including loss of Kit expression that suggests a loss of Interstitial Cells of CajalCrossRefPubMed
13.
Faussone-Pellegrini MS, Grover M, Pasricha PJ, et al. Ultrastructural differences between diabetic and idiopathic gastroparesis. J Cell Mol Med. 2012;16:1573–81.CrossRefPubMedPubMedCentral
14.
O’Grady G, Angeli TR, Du P, et al. Abnormal initiation and conduction of slow-wave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterology. 2012;143:589–598.e1–e3.CrossRefPubMedPubMedCentral
15.••
Angeli TR, Cheng LK, Du P, Wang TH, Bernard CE, Vannucchi MG, et al. Loss of interstitial cells of Cajal and patterns of gastric dysrhythmia in patients with chronic unexplained nausea and vomiting. Gastroenterology. 2015;149(1):56–66.e5. A case-control study of CUNV patients and age-matched controls that demonstrated a significantly lower ICC density along with dysrhythmic slow wave activity in CUNV patients.CrossRefPubMedPubMedCentral
16.
Pasricha PJ, Grover M, Yates K, et al. Gastroparesis and functional dyspepsia of postprandial discomfort phenotype have similar clinical, pathophysiological and histopathological features. Gastroenterology. 2016;150(Issue 4, Supplement 1):S215.CrossRef
17.
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–42.CrossRefPubMed
18.
Langley-DeGroot M, Ma JD, Hirst J, Roeland EJ. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature. J Pain Palliat Care Pharmacother. 2015;29(2):148–52.CrossRefPubMed
19.
Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol. 2015;95(2):214–21.CrossRefPubMed
20.
Yin J, Song J, Lei Y, Xu X, Chen JD. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(9):G796–801.CrossRefPubMed
21.••
Tack J, Ly HG, Carbone F, Vanheel H, Vanuytsel T, Holvoet L, et al. Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol. 2016;14(3):385–392.e4. A randomized, placebo-controlled pilot study that evaluated mirtazapine versus placebo in functional dyspepsia patients and found a reduction in dyspepsia symptom severity and early satiety in the mirtazapine group compared to baseline measurements.CrossRefPubMed
22.•
Jiang SM, Jia L, Liu J, Shi MM, Xu MZ. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol. 2016;22(22):5260–6. A randomized, placebo-controlled trial comparing mirtazapine, paroxetine, and placebo therapy. Mirtazapine worked best with improvement in functional dyspepsia symptoms, depressive symptoms, and weight gain.CrossRefPubMedPubMedCentral
23.
Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149(2):340–9.e2.CrossRefPubMedPubMedCentral
24.
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol otil. 2014;26(4):521–8.CrossRef
25.
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol. 2015;13(7):1256–1263.e1.CrossRefPubMed
26.
Tack J, Rotondo A, Meulemans A, Thielemans L, Cools M. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. Neurogastroenterol Motil. 2016;28(4):487–97.CrossRefPubMed
27.
Carbone F, Rotondo A, Andrews CN, et al. A controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology. 2016;150(Issue 4, Supplement 1):S213–4.CrossRef
28.
29.
Clarke JO, Snape WJ. Pyloric sphincter therapy botulinum toxin, stents, and pyloromyotomy. Gastroenterol Clin N Am. 2015;44:127–36.CrossRef
30.
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103(2):416–23.CrossRefPubMed
31.
Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–8.CrossRefPubMed
32.
Clarke JO, RZ S, Kord Valeshabad A, et al. Through-the- scope transpyloric stent placement improves symptoms and gastric emptying in patients with gastroparesis. Endoscopy. 2013;45(Suppl 2):E189–90.PubMed
33.
Khashab MA, Besharati S, Ngamruengphong S, Kumbhari V, El Zein M, Stein EM, et al. Refractory gastroparesis can be successfully managed with endoscopic transpyloric stent placement and fixation (with video. Gastrointest Endosc. 2015;82(6):1106–9.CrossRefPubMed
34.
Mekaroonkamol P, Li LY, Dacha S, Xu Y, Keilin SD, Willingham FF, et al. Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. Neurogastroenterol Motil. 2016;28(8):1272–7.CrossRefPubMed
35.
Khashab MA, Stein E, Clarke JO, et al. Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video. Gastrointest Endosc. 2013;78:764–8.CrossRefPubMed
36.
Gonzalez JM, Vanbiervliet G, Vitton V, et al. First European human gastric peroral endoscopic myotomy, for treatment of refractory gastroparesis. Endoscopy. 2015;47(Suppl 1):E135–6.PubMed
37.
Chaves DM, de Moura EG, Mestieri LH, et al. Endoscopic pyloromyotomy via a gastric submucosal tunnel dissection for the treatment of gastroparesis after surgical vagal lesion. Gas-trointest Endosc. 2014;80:164.CrossRef
38.
Shlomovitz E, Pescarus R, Cassera MA, et al. Early human experience with per-oral endoscopic pyloromyotomy (POP. Surg Endosc. 2015;29:543–51.CrossRefPubMed
39.
Khashab MA, Ngamruengphong S, Carr-Locke D, Bapaye A, Benias PC, Serouya S, et al. Gastric peroral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy (with video), Gastrointestinal Endoscopy (2016)
40.
Wellington J, Scott B, Kundu S, Stuart P, Koch KL. Effect of endoscopic pyloric therapies for patients with nausea and vomiting and functional obstructive gastroparesis. Auton Neurosci. 2016. Jul 16. pii: S1566-0702(16)30102-3.
Metadaten
Titel
Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis
verfasst von
Kimberly N. Harer, MD
Pankaj J. Pasricha, MD
Publikationsdatum
08.10.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 4/2016
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-016-0113-z

Weitere Artikel der Ausgabe 4/2016

Current Treatment Options in Gastroenterology 4/2016 Zur Ausgabe

Stomach (K Koch, Section Editor)

Newest Drugs for Chronic Unexplained Nausea and Vomiting

Stomach (K Koch, Section Editor)

Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting

Motility (H Parkman and R Schey, Section Editors)

Finding the Right Treatment for Achalasia Treatment: Risks, Efficacy, Complications

Motility (H Parkman and R Schey, Section Editors)

Central Aspects of Nausea and Vomiting in GI Disorders

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Stomach (K Koch, Section Editor)

Diet and Complementary Medicine for Chronic Unexplained Nausea and Vomiting and Gastroparesis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise